AKBA stock forecast
Our latest prediction for Akebia Therapeutics, Inc.'s stock price was made on the Nov. 20, 2019 when the stock price was at 3.34$.
In the short term (2weeks), AKBA's stock price should outperform the market by 5.90%. During that period the price should oscillate between -7.35% and +13.91%.
In the medium term (3months), AKBA's stock price should outperform the market by 7.18%. During that period the price should oscillate between -17.29% and +38.45%.Get email alerts
Create a solid portfolio with AKBA
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
At the moment the company generates 351M USD in revenues.
On its last earning announcement, the company reported a loss of -2.21$ per share.
The book value per share is 2.91$
Three months stock forecastNov. 20, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|